ESR1 and breast carcinoma: In this context, the expression levels of proliferation-related genes can define two clinically distinct molecular subtypes of ER+ breast carcinoma—low-proliferative luminal-A and high-proliferative luminal-B—that differ in treatment response and clinical outcome [6,7,8,9,10].